KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Income (2016 - 2025)

Emergent BioSolutions' Net Income history spans 14 years, with the latest figure at -$54.6 million for Q4 2025.

  • For Q4 2025, Net Income fell 74.44% year-over-year to -$54.6 million; the TTM value through Dec 2025 reached $52.6 million, up 127.6%, while the annual FY2025 figure was $52.6 million, 127.6% up from the prior year.
  • Net Income reached -$54.6 million in Q4 2025 per EBS's latest filing, down from $51.2 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $177.9 million in Q4 2021 to a low of -$283.1 million in Q2 2024.
  • Average Net Income over 5 years is -$44.7 million, with a median of -$32.0 million recorded in 2021.
  • Peak YoY movement for Net Income: soared 657.6% in 2021, then crashed 4932.43% in 2023.
  • A 5-year view of Net Income shows it stood at $177.9 million in 2021, then plummeted by 137.66% to -$67.0 million in 2022, then increased by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then tumbled by 74.44% to -$54.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Net Income are -$54.6 million (Q4 2025), $51.2 million (Q3 2025), and -$12.0 million (Q2 2025).